Navigation Links
Misonix Announces New Distribution Agreement for Saudi Arabia and Other Middle Eastern Countries
Date:11/12/2009

FARMINGDALE, N.Y., Nov. 12 /PRNewswire-FirstCall/ -- Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has entered into a new, three year, exclusive distribution agreement with Dalpharma, Ltd., based in Riyadh, Saudi Arabia, for the distribution of the SonicOne® Ultrasonic Wound Debrider. The agreement provides Dalpharma with the rights to sell in Saudi Arabia, Yemen, Oman, and Egypt, and includes minimum purchase requirements.

Dalpharma is recognized in several Middle Eastern countries as a service oriented distributor of state-of-the-art medical devices and capital equipment, with special emphasis on the wound care market segment.

The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.

"Misonix welcomes Dalpharma to our expanding family of distributors and represents one of our early partnerships in the important Saudi Arabian and Middle East market places," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Dalpharma's reputation as a high integrity, customer focused sales organization is well known to Misonix."

About Misonix:

Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

    Investor Relations Contact:
    Cameron Associates, Inc.
    212-245-4577
    Kevin@cameronassoc.com

SOURCE Misonix, Inc.


'/>"/>
SOURCE Misonix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Schedules Fourth Quarter and Fiscal Year 2009 Financial Results Conference Call; October 1, 2009 at 4:30 p.m. Eastern
2. Misonix Reports Fourth Quarter and Fiscal Year 2009 Financial Results
3. Misonix, Inc. Announces the Sale of Sonora Medical Systems for $8 Million
4. Misonix Announces New Distribution Agreement for United Kingdom and Republic of Ireland
5. Misonix Schedules First Quarter 2010 Financial Results Conference Call; November 16, 2009 at 4:30 p.m. Eastern
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... YORK , Feb. 22, 2017 This report ... Thousand. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the period 2015 ... these markets. Market data and analytics are derived from primary ...
(Date:2/23/2017)... , Feb. 22, 2017 Summary ... lymphoma partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605669-summary/view-report.html Description The ... 2010 report provides understanding and access to partnering ... leading healthcare companies. - Trends in ...
(Date:2/22/2017)... , Feb. 22, 2017 General ... ASPs, Market Value & Growth Trends - Market ... Competitive Analysis for each chapter segment - Section ... the full report: https://www.reportbuyer.com/product/4665946/ ... different delivery methods: articulated arm lasers, fiber-delivered lasers ...
Breaking Medicine Technology:
(Date:2/23/2017)... California (PRWEB) , ... February 23, 2017 , ... ... Sports Development will host a diverse symposium on “Doping in Sport: ... Law and Sheppard Mullin Richter & Hampton LLP. The symposium will be held ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... uncertainty in clinical trials, today announced that Premier Research, a leading clinical development ... , Clinical trials are becoming increasingly complex, due in part to an array ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... with the Rhode Island Consortium for Autism Research and Treatment (RI-CART) and Cinemaworld ... with autism spectrum disorder (ASD) to see films in an environment that accommodates ...
(Date:2/23/2017)... ... , ... Top cosmetic and periodontal dentist Dr. Mahnaz Rashti announced ... Indiegogo campaign . Individuals are now able to contribute to the local initiative, which ... a participating patient or through an Indiegogo donation. The entirety of proceeds will go ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thomas Vas-Don suffered ... exercise regime, the author was able to successfully recover. In “ Origin & Insertion ... for various sources on the principals of massage, anatomy , trigger points ...
Breaking Medicine News(10 mins):